Impact of ocrelizumab on patient-reported fatigue and quality of life in participants with relapsing multiple sclerosis treated for the first time with ocrelizumab

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2021
This article has no abstract
Epistemonikos ID: 5baf6dedf0b10e55575d0d020be2a7864d475019
First added on: Nov 03, 2021